Myriad Genetics Third Quarter 2024 Financial Earnings

11/07/2024 | 1:30pm PST / 4:30pm EST

Participant Dial-in:
United States – New York +1.646.968.2525
USA & Canada – Toll-Free +1.888.596.4144
Conference ID 6257274

Listen to the webcast

Events & Presentations

View all events

Financial Reports and Filings

Date Filing Title Downloads
12/10/2024 3 Initial filing by director officer or owner of more than ten percent RTF XLS PDF HTML XBRL
12/10/2024 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
12/02/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
11/26/2024 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
11/14/2024 SC 13G/A An amendment to the SC 13G filing RTF XLS PDF HTML XBRL
11/08/2024 10-Q Quarterly report which provides a continuing view of a company's financial position RTF XLS PDF HTML XBRL
11/07/2024 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
10/11/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
10/11/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
10/10/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
View all filings

Latest News

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing Thumbnail

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Dec 10, 2024 | Financial

Read more
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member Thumbnail

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Dec 10, 2024 | Products | Corporate

Read more
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines Thumbnail

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Dec 10, 2024 | Products

Read more
View all news releases

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics